Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-Label Trial With TMC125 in HIV-1 Infected Subjects, Who Were Randomized to a TMC125 Treatment Arm in a Sponsor-Selected TMC125 Trial and Were Treated for at Least 48 Weeks

NCT00128830 is registered in ClinicalTrials.gov with Tibotec Pharmaceuticals, Ireland as lead sponsor.

NCT NCT00128830
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00128830 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-Label Trial With TMC125 in HIV-1 Infected Subjects, Who Were Randomized to a TMC125 Treatment Arm in a Sponsor-Selected TMC125 Trial and Were Treated for at Least 48 Weeks
Lead sponsor
Tibotec Pharmaceuticals, Ireland
Phase
Phase 2
Overall status
Completed
Start date
June 30, 2005
Completion date
August 31, 2008
Enrollment
211 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

human immunodeficiency virus type 1